For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| Revenue | - | 0* | ||
| Cost of revenues | - | 0* | ||
| Gross profit | - | 0* | ||
| Gain on lease termination | - | 0* | ||
| Research and development | 1,915,000 | 1,039,000* | ||
| General and administrative | 1,631,000 | 1,290,750* | ||
| Impairment of goodwill | 2,044,000 | - | ||
| Total operating expenses | 5,590,000 | 2,329,750* | ||
| Loss from operations | -5,590,000 | -2,329,750* | ||
| Change in fair value of convertible notes | - | 0* | ||
| Change in fair value to bridge notes derivative liability | - | 0* | ||
| Change in fair value of contingent consideration | - | 0* | ||
| Forward Sales Contract Expense | - | -1,470,500* | ||
| Change in fair value of warrant liabilities | - | -250* | ||
| Interest income | - | 20,750* | ||
| Interest income, net | 44,000 | -6,750* | ||
| Other income, net | - | 53,750* | ||
| Gains Losses On Extinguishment Of Debt | - | 200,000* | ||
| Total other income (expense), net | 44,000 | -1,202,500* | ||
| Loss before income taxes | -5,546,000 | -3,532,250* | ||
| Benefit (provision) for income taxes | -40,000 | -11,250* | ||
| Net loss | -5,506,000 | -3,521,000* | ||
| Series a preferred stock dividend | - | 4,000* | ||
| Net loss attributable to common stockholders | - | -3,525,000 | ||
| Basic EPS | -6.95 | -0.559 | ||
| Diluted EPS | -6.95 | -0.559 | ||
| Basic Average Shares | 792,000 | 6,307,000 | ||
| Diluted Average Shares | 792,000 | 6,307,000 | ||
Ernexa Therapeutics Inc. (ERNAW)
Ernexa Therapeutics Inc. (ERNAW)